Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06225596 · ClinicalTrials.gov registry record · Phase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
A Phase 2 study of Metastatic Urothelial Cancer, sponsored by BicycleTx Limited.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 956
- Enrollment target
- 20
- Study locations
NCT06225596 is a Phase 2 study of Metastatic Urothelial Cancer that is actively recruiting participants, run by BicycleTx Limited. The registered enrollment target is 956 participants, above the 461-participant average among 5 other Metastatic Urothelial Cancer trials with a reported enrollment target (107% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06225596, a Phase 2 study of Metastatic Urothelial Cancer, is actively recruiting participants, sponsored by BicycleTx Limited.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 956 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic urothelial cancer (UC). The study includes a dose selection phase followed by an adaptive design continuation. The study is comprised of 2 cohorts. Cohort 1 will include participants who have not received any prior systemic therapy for locally advanced or metastatic UC and are eligible to receive platinum-based chemotherapy, whereas Cohort 2 will include participants who have received ≥ 1 prior systemic therapy for locally advanced or metastatic UC.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG BT8009
- DRUG Gemcitabine + cisplatin Or carboplatin
Study Locations (20)
Florida
- Cancer Specialists of North Florida - Jacksonville
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
- AP Medical Research - Miami
- Mount Sinai Medical Center of Florida, Inc. - Miami Beach
- Moffitt - Tampa
California
- Virginia K. Crosson Cancer Center at St. Jude Medical Center - Fullerton
- University of California - Irvine Medical Center - Orange
- University of California, San Francisco (UCSF) - San Francisco
- Adventist Health St. Helena - St. Helena
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Rocky Mountain Cancer Center - Denver
Connecticut
- Yale University School of Medicine - Yale Cancer Center - New Haven
Delaware
- Medical Oncology Hematology Consultants - Newark
Illinois
- Southern Illinois University (SIU) - Simmons Cancer Institute - Springfield
Iowa
- Mission Cancer + Blood - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 956 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06225596
The ClinicalTrials.gov registry entry for NCT06225596 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 956 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 461-participant average among 5 other Metastatic Urothelial Cancer trials with a reported enrollment target (107% higher). The listed sponsor is BicycleTx Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Urothelial Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06225596 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT06225596 about?
NCT06225596 is a clinical study titled "Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)". This is a global, multicenter, randomized, open-label study, with an adaptive design. The main objective of the study is to measure the efficacy and safety of BT8009 (zelenectide pevedotin) as monotherapy and in combination with pembrolizumab in participants with locally advanced or metastatic uroth...
What is the current status of trial NCT06225596?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 956 participants. The study started on 2024-01-24. Estimated completion is 2030-12.
What conditions does trial NCT06225596 study?
This clinical trial studies the following conditions: Metastatic Urothelial Cancer.
What interventions are being tested in trial NCT06225596?
The interventions under investigation include: Pembrolizumab (DRUG), BT8009 (DRUG), Gemcitabine + cisplatin Or carboplatin (DRUG).
Who is sponsoring clinical trial NCT06225596?
This trial is sponsored by BicycleTx Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06225596 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Urothelial Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
RECRUITING · Phase 2
-
Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
COMPLETED · Phase 2
-
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
COMPLETED · Phase 2
-
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.